Profile
Corporate information
Official name
Hylomorph AG
Tens of millions of people live today with one or more surgical implant. Every time a patient receives a surgical implant, the immune system initiates a foreign body reaction. The implant becomes covered by a thick layer of fibrotic tissue, which hardens and contracts over time in an attempt of isolating, killing and expelling the foreign body. Hylomorph aims at minimizing post-surgical complications in medical implants, thus improving patients' quality-of-life and reducing associated healthcare costs. Hylomorph provides clinicians with ready-to-use conformal covers for implantable medical devices. A proprietary technology minimizes the incidence of post-operative complications such as infection, by preventing the onset of fibrotic tissue encapsulation and microbial contamination.
Funding
Funding rounds
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Verve Capital Partners AG | Switzerland | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Fongit Seed Invest | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Lichtsteiner Stiftung | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Zurich Cantonal Bank | Switzerland | Initial investment. Round participant. |